Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05613608 · ClinicalTrials.gov registry record · Phase 2
Alcohol Use Disorder and Cannabidiol
A Phase 2 study of Alcohol Use Disorder, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT05613608 is a Phase 2 study of Alcohol Use Disorder that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 180 participants, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05613608, a Phase 2 study of Alcohol Use Disorder, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum CBD and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with alcohol use disorder. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol
Study Locations (1)
Colorado
- University of Colorado Anschutz - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2023-04-30 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05613608
The ClinicalTrials.gov registry entry for NCT05613608 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (45% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05613608 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT05613608 about?
NCT05613608 is a clinical study titled "Alcohol Use Disorder and Cannabidiol". This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum CBD and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with alcohol use disorder. If eligible for the study, subjects will be randomized to re...
What is the current status of trial NCT05613608?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2023-04-30. Estimated completion is 2027-04.
What conditions does trial NCT05613608 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT05613608?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT05613608?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05613608 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.